Valbenazine Tosylate Patent Expiration
Valbenazine Tosylate is Used for treating Huntington's chorea and tardive dyskinesia in patients without concomitant use of strong CYP3A4 inducers. It was first introduced by Neurocrine Biosciences Inc
Valbenazine Tosylate Patents
Given below is the list of patents protecting Valbenazine Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ingrezza | US10065952 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza | US10844058 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza | US10851103 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza | US10851104 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza | US10857137 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US10857148 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US10874648 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US10906902 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | Dec 22, 2036 | Neurocrine |
| Ingrezza | US10906903 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | Dec 22, 2036 | Neurocrine |
| Ingrezza | US10912771 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US10919892 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | Dec 22, 2036 | Neurocrine |
| Ingrezza | US10940141 | Methods for the administration of certain VMAT2 inhibitors | Aug 10, 2040 | Neurocrine |
| Ingrezza | US10952997 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US10993941 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US11026931 | Methods for the administration of certain VMAT2 inhibitors | Aug 14, 2039 | Neurocrine |
| Ingrezza | US11026939 | High dosage valbenazine formulation and compositions, methods, and kits related thereto | Sep 18, 2038 | Neurocrine |
| Ingrezza | US11040029 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US11311532 | High dosage valbenazine formulation and compositions, methods, and kits related thereto | Sep 18, 2038 | Neurocrine |
| Ingrezza | US11439629 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza | US11654142 | Methods for the administration of certain VMAT2 inhibitors | Nov 14, 2038 | Neurocrine |
| Ingrezza | US8039627 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto | Apr 11, 2031 | Neurocrine |
| Ingrezza | US8357697 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto | Nov 08, 2027 | Neurocrine |
| Ingrezza Sprinkle | US10065952 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza Sprinkle | US10844058 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza Sprinkle | US10851103 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza Sprinkle | US10851104 | Valbenazine salts and polymorphs thereof | Oct 28, 2036 | Neurocrine |
| Ingrezza Sprinkle | US10857137 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US10857148 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US10874648 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US10906902 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | Dec 22, 2036 | Neurocrine |
| Ingrezza Sprinkle | US10906903 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | Dec 22, 2036 | Neurocrine |
| Ingrezza Sprinkle | US10912771 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US10919892 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | Dec 22, 2036 | Neurocrine |
| Ingrezza Sprinkle | US10940141 | Methods for the administration of certain VMAT2 inhibitors | Aug 10, 2040 | Neurocrine |
| Ingrezza Sprinkle | US10952997 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US10993941 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US11026931 | Methods for the administration of certain VMAT2 inhibitors | Aug 14, 2039 | Neurocrine |
| Ingrezza Sprinkle | US11026939 | High dosage valbenazine formulation and compositions, methods, and kits related thereto | Sep 18, 2038 | Neurocrine |
| Ingrezza Sprinkle | US11040029 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US11311532 | High dosage valbenazine formulation and compositions, methods, and kits related thereto | Sep 18, 2038 | Neurocrine |
| Ingrezza Sprinkle | US11439629 | Methods for the administration of certain VMAT2 inhibitors | Oct 10, 2037 | Neurocrine |
| Ingrezza Sprinkle | US11654142 | Methods for the administration of certain VMAT2 inhibitors | Nov 14, 2038 | Neurocrine |
| Ingrezza Sprinkle | US8039627 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto | Apr 11, 2031 | Neurocrine |
| Ingrezza Sprinkle | US8357697 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto | Nov 08, 2027 | Neurocrine |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Valbenazine Tosylate Generics
Several generic applications have been filed for Valbenazine Tosylate.
Given below is the list of companies who have filed for Valbenazine Tosylate generic.
1. LUPIN LTD
Lupin Ltd has filed for 2 different strengths of generic version for Valbenazine Tosylate. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 40MG BASE | capsule | Prescription | ORAL | AB | Apr 5, 2024 |
| EQ 80MG BASE | capsule | Prescription | ORAL | AB | Apr 5, 2024 |